David Fingold
Hoya Corporation
7741-JP
PAST TOP PICK
Jan 14, 2021
(A Top Pick Dec 02/19, Up 40%) Masters of making glass. Second largest eye glass lens maker in the world. Their Pentax lens unit will benefit from pent-up demand in endoscopy. Well positioned in current environment.
Hard drives refuse to die. Hoya is the only supplier of glass platters, so that's where he's invested. Hard drives will be transitioning from aluminum to glass over the next 5 years.
Lots of pent-up demand for eyeglass lenses and endoscopy procedures. Pent-up demand is one of his themes for the early stage of an economic recovery. (Price target is in yuan.) Yield is 0.65%. (Analysts’ price target is $14486.36)
The price target is in Japanese yen. Expertise is in glass. There is pent-up demand in eye glasses. They are number 2 in the world. They are also a producer of a substrate for hard disk platters. They also dominate the photo lithography for semiconductors. A play on the extreme ultraviolet lithography. (Analysts’ price target is $16600.00)
Second largest producer of eye glasses and other glass products such as endoscopes, etc. Very high quality company with strong margins and long term record of growth. There is growth opportunity in eye glasses. Endoscope area could present a challenge with possible switch to disposable technology. Stewards of capital eg. dividend growth. An entrepreneurial company, one of the best in Japan.
Very good longer term. Reasonable balance sheet. Shareholder support is quite good. Reasonable returns. Beneficiary of semiconductor business. With volatility, stock probably moves further south, so chance to pick it up lower. Be aware that Japan's central bank is playing in the currency market to support the yen.
(A Top Pick Apr 14/21, Down 6%) It is a world leader in production of low cost eyeglasses. It also produces components in semi-conductors. He is disappointed in the short term price of the stock but the long term prospects are good,
(A Top Pick Aug 06/21, Down 15%) Frustrating stock move movement because it is in healthcare and is the second largest producer of endoscopes and eye glass lenses. However the market is gravitating towards pharmaceutical. Also a smaller part is tied to the tech space which is doing well and could be doing even better when techs improve. He is a long term holder but doesn't know the long term catalysts.